Stock Market Today: Dow futures dip from record highs as rally pauses
Merck & Co.’s stock fell 0.5% premarket Wednesday, after the drug company said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal ...
Merck Says Phase 3 KEYFORM-007 Study Did Not Meet Primary Goal Of Overall Survival
Merck & Co Inc. (MRK) on Wednesday said its Phase 3 KEYFORM-007 study evaluating the company's drug candidate favezelimab in ...
ENDPOINTS NEWS57m
Mer­ck­'s LAG-3 plus Keytru­da com­bo fails Phase 3 in col­orec­tal can­cer
Merck’s efforts to combine its PD-1 blockbuster Keytruda with an experimental LAG-3 inhibitor hit a stumbling block Wednesday ...
Merck says trial of combination treatment for colon cancer failed to meet main goal
Merck & Co.’s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet ...